Hodgkin lymphoma (HL) is an oncological disease with high likelihood of cure. At Protheragen, we work on creating groundbreaking therapeutics and precise animal models to expedite the preclinical studies of therapies for HL. With our proficiency, you can be assured that your research will get the most appropriate and dependable attention, thus fast-tracking your path to developing a drug.
Hodgkin lymphoma (HL) is a type of blood cancer that is both rare and treatable. It begins in the lymphatic system, specifically in the B lymphocytes. Hodgkin lymphoma is marked by the proliferation of Reed-Sternberg cells and commonly presents as painless enlargement of lymph nodes in the neck, chest, and armpits, with accompanying systemic signs like fever, night sweat, and weight loss. The expected yearly rate of occurrence of HL is around 3 cases for every 100,000 individuals.
| Disease Forms | Prevalence | Tumor Cells | Manifestation |
|---|---|---|---|
| Classical HL (cHL) | ~95% of HL cases | Hodgkin/Reed-Sternberg (HRS) cells | Aggressive and systemic symptoms |
| Nodular Lymphocyte-Predominant HL (NLPHL) | ~5% of HL cases | Lymphocyte predominant (LP) cells | Indolent and usually localized |
Hodgkin lymphoma (HL) arises from genetically altered B cells that evade apoptosis and proliferate abnormally. Classical HL (cHL) is driven by malignant Hodgkin/Reed-Sternberg (HRS) cells. In cHL, HRS cells exhibit constitutive activation of the NF-κB and JAK/STAT signaling pathways, often due to Epstein-Barr virus (EBV) infection or genetic mutations such as TNFAIP3 and SOCS1. These tumor cells evade immunity by growing in an immunosuppressive microenvironment rich in regulatory T cells and cytokines.
Fig.1 Key features of Hodgkin/Reed-Sternberg (HRS) cells and classical HL (cHL). (Weniger, Marc A., and Ralf Küppers., 2021)
| Drug Names | Mechanism of Action | Targets | NCT Number | Research Phase |
|---|---|---|---|---|
| MDX-1401 | Enhances antibody-dependent cellular cytotoxicity (ADCC). | CD30 | NCT00634452 | Phase I |
| Doxorubicin | Intercalates DNA, inhibits topoisomerase II, generates reactive oxygen species. | DNA/Topoisomerase II | NCT06235047 | Approved |
| Brentuximab Vedotin | Delivers monomethyl auristatin E (MMAE) to CD30+ cells. | CD30 | NCT03576378 | Approved |
| Pembrolizumab and ATRA | Pembrolizumab: Blocks PD-1/PD-L1 and enhances T-cell activity. | PD-1 | NCT06484920 | Phase II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
As a leading research service provider, Protheragen is dedicated to advancing diagnostic and therapeutic solutions for Hodgkin lymphoma (HL), a rare and severe lymphoproliferative disorder. Our comprehensive therapeutic development services encompass small molecule drug, antibodies, and cell therapy. These innovative approaches are meticulously evaluated in exacting disease models to expedite the transformation of scientific breakthroughs into commercialization.
Specializing in preclinical research for drug development, Protheragen offers a comprehensive solution that includes pharmacodynamics (PD), pharmacokinetic (PK) and toxicology studies to thoroughly validate and optimize therapies for Hodgkin lymphoma (HL). If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
Myeloproliferative Disorders (MPDs)
Bone Marrow Failure Syndromes (BMFS)
